KR20230146025A - 신규 바이사이클릭 펩티드 - Google Patents

신규 바이사이클릭 펩티드 Download PDF

Info

Publication number
KR20230146025A
KR20230146025A KR1020237027582A KR20237027582A KR20230146025A KR 20230146025 A KR20230146025 A KR 20230146025A KR 1020237027582 A KR1020237027582 A KR 1020237027582A KR 20237027582 A KR20237027582 A KR 20237027582A KR 20230146025 A KR20230146025 A KR 20230146025A
Authority
KR
South Korea
Prior art keywords
amino acid
bicyclic peptide
cancer
peptide mimetic
alanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237027582A
Other languages
English (en)
Korean (ko)
Inventor
수다 라오
Original Assignee
더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021900114A external-priority patent/AU2021900114A0/en
Application filed by 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 filed Critical 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치
Publication of KR20230146025A publication Critical patent/KR20230146025A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020237027582A 2021-01-19 2022-01-19 신규 바이사이클릭 펩티드 Pending KR20230146025A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021900114A AU2021900114A0 (en) 2021-01-19 Novel bicyclic peptipes
AU2021900114 2021-01-19
PCT/AU2022/050023 WO2022155704A1 (en) 2021-01-19 2022-01-19 Novel bicyclic peptides

Publications (1)

Publication Number Publication Date
KR20230146025A true KR20230146025A (ko) 2023-10-18

Family

ID=82548163

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237027582A Pending KR20230146025A (ko) 2021-01-19 2022-01-19 신규 바이사이클릭 펩티드

Country Status (9)

Country Link
US (1) US20240117005A1 (https=)
EP (1) EP4281486A4 (https=)
JP (1) JP2024504136A (https=)
KR (1) KR20230146025A (https=)
CN (1) CN117062842A (https=)
AU (1) AU2022209878A1 (https=)
CA (1) CA3208598A1 (https=)
IL (1) IL304545A (https=)
WO (1) WO2022155704A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121108243A (zh) * 2025-01-03 2025-12-12 中国药科大学 一种非核糖体多肽化合物及其合成基因簇bnp37和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US10585100B2 (en) * 2015-04-30 2020-03-10 Kyoto University Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index
WO2017072280A1 (en) * 2015-10-30 2017-05-04 Affibody Ab New polypeptide having affinity to pd-l1
WO2018115203A1 (en) * 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
CN111936509A (zh) * 2018-01-15 2020-11-13 艾比克斯治疗私人有限公司 蛋白质分子及其用途
JP2019189591A (ja) * 2018-04-27 2019-10-31 日東電工株式会社 ヒトｐｄ−ｌ１結合性ペプチド
US12551567B2 (en) * 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1

Also Published As

Publication number Publication date
JP2024504136A (ja) 2024-01-30
EP4281486A4 (en) 2025-01-08
US20240117005A1 (en) 2024-04-11
CA3208598A1 (en) 2022-07-28
WO2022155704A1 (en) 2022-07-28
IL304545A (en) 2023-09-01
EP4281486A1 (en) 2023-11-29
AU2022209878A1 (en) 2023-09-07
CN117062842A (zh) 2023-11-14

Similar Documents

Publication Publication Date Title
KR101653774B1 (ko) 올리고펩타이드 화합물 및 이의 용도
US10105420B2 (en) Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
CN109154613A (zh) 用于监测和治疗癌症的方法
CA3083373A1 (en) Enhancing t-cell function and treating a t-cell dysfunctional disorder with a combination of an lsd inhibitor and a pd1 binding antagonist
KR20200003422A (ko) 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
JP2013502421A (ja) 癌治療のためのｃｄ４４融合タンパク質の使用方法
JP7101118B2 (ja) 異常ｗｎｔシグナル伝達の処置のための安定化ｂｃｌ９ペプチド
KR20210079311A (ko) 육종성 신장암에 대한 진단과 치료 방법
JP2021510538A (ja) タンパク質性分子およびその使用
US20130316958A1 (en) Highly potent peptides to control cancer and neurodegenerative diseases
WO2007117038A1 (ja) 癌の予防・治療剤
KR20230146025A (ko) 신규 바이사이클릭 펩티드
JP5475406B2 (ja) Ｇｂｓ毒素受容体
KR20180066237A (ko) 항-암 및 항-염증 치료제 및 이의 방법
KR20210062634A (ko) 3중-음성 유방암에 대한 진단 방법
CA3073375A1 (en) Fusion protein of dctn1 protein with ret protein
WO2023056527A1 (en) Proteinaceous molecules and uses therefor
JP2025527370A (ja) ヒストンメチルトランスフェラーゼ核局在化の新規阻害剤
KR102315997B1 (ko) Baf57 재조합 융합 단백질 및 이의 용도
US20250325684A1 (en) Potent anti-cancer cyclotides
AU2018363880B2 (en) Immunogenic compositions and uses therefor
EP1503780B1 (en) Androgen-regulated pmepa1 gene and methods of using the same to inhibit cancer cell growth
Oldberg Elucidating the Novel Role for Core Binding Factor beta in Osteosarcoma Protein Translation
JP4634302B2 (ja) テトラヒドロ葉酸合成酵素遺伝子
US20220267390A1 (en) Mps modified peptides and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230814

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250120

Comment text: Request for Examination of Application